RCEL AVITA Medical, Inc.
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR AVITA Medical, Inc. (RCEL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No new risk factors added this quarter; risk profile unchanged since 2024 Annual Report
- • No material updates to existing risks since prior 10-K and Q1 2025 10-Q filings
Quarterly Financial SummaryXBRL
Revenue
$17M
Net Income
-$13M
Gross Margin
81.3%
Operating Margin
-53.6%
Net Margin
-77.3%
ROE
197.8%
Total Assets
$64M
Source: XBRL data from AVITA Medical, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on AVITA Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.